Bicara Therapeutics (NASDAQ:BCAX) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Bicara Therapeutics (NASDAQ:BCAX) issued its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Stock Up 2.9 %

Bicara Therapeutics stock traded up $0.39 during mid-day trading on Friday, reaching $13.79. 82,088 shares of the company were exchanged, compared to its average volume of 465,206. The firm’s fifty day moving average is $13.01. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09.

Analyst Ratings Changes

BCAX has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday. Finally, HC Wainwright upped their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.